Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
Fiche publication
Date publication
février 2023
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AKLADIOS Chérif
Tous les auteurs :
Jiao XD, Qin BD, Wang Z, Liu K, Wu Y, Ling Y, Qin WX, Wang MM, Yuan LY, Barreto SG, Kim AW, Mak K, Li H, Xu YY, Qiu XM, Wu M, Jin M, Xu LC, Zhong Y, Yang H, Chen XQ, Zeng Y, Shi J, Zhu WY, Ding QQ, Jia W, Liu SF, Zhou JJ, Shen H, Yao SH, Guo ZJ, Li T, Zhou PJ, Dong XW, Lu WF, Coleman RL, Akce M, Akladios C, Puccetti F, Zang YS
Lien Pubmed
Résumé
We evaluated he effects of molecular guided-targeted therapy for intractable cancer. Also, the epidemiology of druggable gene alterations in Chinese population was investigated.
Mots clés
basket trial, gene alteration, intractable cancer, precision medicine, targeted therapy
Référence
Front Oncol. 2023 02 23;13:860711